Revolutionary products that save lives.
BC3 Technologies, Inc. is a privately held medical device company focused on the development and commercialization of aerosolized hemostatic products that help save lives. A certified minority-owned company, BC3 was founded on the idea that there needs to be a change in the way health care professionals and first responders manage life-threatening arterial bleeding.
Meeting a critical need
in the management of arterial bleeding.
Each year, 40 percent of critically wounded people with arterial bleeding die in transit to the hospital. Bleeding wounds, including gunshot wounds, that cannot be treated with standard hemostatic methods, such as applying pressure with bandages, remain a leading cause of potentially preventable deaths. Arterial bleeding also increases the chances of spreading blood borne diseases.
In addition, and independent of the mechanism of injury, hemorrhagic shock consistently represents the second-leading cause of early deaths among the injured.
”We recognized a critical need to change the way wounds and significant bleeding were being treated in emergency and trauma situations.Wayne Grube Jr.CEO & Founder
A more effective solution in the treatment of arterial bleeding.
SEAL Hemostatic Wound Spray
The first and only aerosolized chitosan for management of serious arterial hemorrhage.
SEAL Hemostatic Wound Spray is designed to meet the challenges of arterial bleeding. When sprayed on a wound and upon contact with blood or exudate, SEAL quickly forms a strong barrier over the wound and helps stop the bleeding within seconds and without pain – drastically increasing the likelihood of victim survival.
SEAL was developed for emergency situations, surgical environments, and for the battlefield where response time to hemorrhaging is the critical difference between life and death.
- For moderate to severe external bleeding wounds
- For emergency use of temporary external treatment
- For controlling moderate to severe bleeding
Multiple applications in multiple environments.
The product is compact, easy to carry, and can be administered by first responders, patients, professional medical staff, or caregivers.
SEAL aerosol containers come in two sizes: a three-second can for stab and bullet wounds and a 10-second can for wounds larger than four inches or for appendages that have been severed. Unlike bandage or granule-based chitosan products, SEAL can be applied under windy and wet conditions and in low-light.
SEAL has undergone preliminary efficacy studies with several organizations, including the U.S. Army Institute of Surgical Research. It is the only chitosan-based aerosol spray product available for treating wounds. Due to its novel spray design, SEAL can be applied directly to complex 3D wound architectures and can be forced into openings, such as gunshot wounds.
We help empower front-line emergency responders to do their jobs.
BC3 helps save lives by putting SEAL wound spray in the hands of paramedics, police officers, military personnel, doctors and other emergency responders who deal with hemorrhage-related trauma every day. SEAL not only stop bleeding faster and more effectively, but it also reduces the risk of wound infections and helps prevents the growth of harmful bacteria.
Meet the BC3 leadership team.
Passionate, like-minded professionals with the simple but critical goal of saving lives.
BC3 Technologies Receives FDA Clearance for SEAL Hemostatic Wound Spray
FDA Clearance Paves Way for Commercial Use of First and Only Aerosolized Chitosan for Management of Serious Arterial Hemorrhage